EVAX News - Candlesense

Evaxion to present at several conferences during the second half of 2025

COPENHAGEN, Denmark, August 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting data a...

Conference

15 days ago

Evaxion announces business update and second quarter 2025 financial results

COPENHAGEN, Denmark, August 14, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update ...

What macro or sector trends (e.g., AI adoption in biotech, vaccine demand) could amplify or mitigate the impact of this news on EVAX shares? How might the sentiment score of 20 (presumably low) reflect broader analyst sentiment, and why might it differ from the actual news tone? Did the update include any new partnership, licensing, or acquisition activity that could affect revenue streams?

Earnings

28 days ago